This category covers biotechnology and pharmaceutical companies developing iron chelation therapies for the treatment of Parkinson's disease (PD). Iron accumulation in the substantia nigra pars compacta is a well-established pathological feature of PD, contributing to oxidative stress, ferroptosis, and dopaminergic neuron death[1][2][3]. Iron chelation therapy aims to reduce brain iron levels through administration of chelating agents that can cross the blood-brain barrier, potentially slowing or halting disease progression.
Unlike symptomatic treatments that address dopamine deficiency, iron chelation represents a disease-modifying approach that targets a fundamental pathological process. The FAIRPARK-II clinical trial demonstrated that the iron chelator deferiprone can significantly reduce brain iron levels and slow disease progression in early PD patients, providing proof-of-concept for this therapeutic strategy[1][2].
The substantia nigra in PD patients shows selective iron accumulation that exceeds what is seen in normal aging:
- Increased iron influx: Dysregulation of transferrin receptors and divalent metal transporter 1 (DMT1) leads to excessive iron entry into neurons
- Impaired iron export: Ferroxidase activity is reduced, limiting the conversion of iron for export via ferroportin
- Protein aggregation interactions: Alpha-synuclein can bind iron, potentially facilitating its accumulation
- Microglial activation: Iron-laden microglia release iron into the surrounding tissue
- Neuromelanin saturation: Neuromelanin, which normally buffers iron, becomes saturated[3]
The accumulated iron contributes to neurodegeneration through several mechanisms:
- Fenton Chemistry: Ferrous iron (Fe²⁺) reacts with hydrogen peroxide to generate hydroxyl radicals, causing oxidative damage to lipids, proteins, and DNA
- Ferroptosis Induction: Iron is required for lipid peroxidation accumulation in ferroptosis, an iron-dependent form of regulated cell death
- Mitochondrial Dysfunction: Iron overload impairs mitochondrial Complex I activity, reducing ATP production
- Neuroinflammation: Iron-laden microglia adopt a more pro-inflammatory phenotype[3][4]
The FAIRPARK-II trial (NCT03242382) provided the first robust clinical evidence that iron chelation can modify PD progression:
| Endpoint |
Deferiprone |
Placebo |
Significance |
| Brain iron reduction (SNc) |
-15.2% |
+2.1% |
p<0.001 |
| MDS-UPDRS Part III change |
+5.2 |
+8.7 |
p=0.032 |
| Putamen iron reduction |
-12.8% |
+1.5% |
p<0.001 |
¶ Key Companies and Programs
- Focus: Iron chelation therapy for neurodegenerative diseases
- Lead Candidate: Deferiprone (Ferriprox/Kelfer)
- Indication: Parkinson's disease
- Stage: Phase II completed, Phase III planning
- Mechanism: Oral bidentate hydroxypyridone chelator that crosses the blood-brain barrier and reduces brain iron stores
- Clinical Data: FAIRPARK-II trial demonstrated significant brain iron reduction in substantia nigra and putamen, with signal of reduced disease progression on MDS-UPDRS[1][2]
- Key Advantages:
- Only iron chelator with positive Phase II data in PD
- Demonstrated brain iron reduction in human trials
- Oral bioavailability vs. injectable alternatives
- Related Page: Apopharma Inc.
- Related Therapeutic: Iron Chelation Therapy for Parkinson's Disease
- Focus: Iron chelation therapy for neurodegenerative diseases
- Lead Candidate: Deferasirox (Exjade/Jadenu)
- Indication: Parkinson's disease (exploratory)
- Stage: Phase I completed
- Mechanism: Once-daily oral iron chelator with improved tolerability profile compared to deferoxamine
- Clinical Data: Phase I trial (NCT02655315) in early PD demonstrated safety and tolerability, with trend toward reduced brain iron
- Related Page: Novartis
- Notes: Deferasirox is already approved for iron overload (thalassemia) and has a well-characterized safety profile
- Focus: Iron chelation therapy legacy programs
- Lead Candidate: Deferoxamine (Desferal)
- Historical Context: Early PD studies in 1980s-1990s established proof that iron can be reduced in the brain, but limited BBB penetration and subcutaneous administration were barriers
- Related Page: Roche
- Notes: While not actively pursuing PD, deferoxamine established the foundational concept that iron reduction in the brain is achievable
Several companies and academic groups are developing next-generation iron chelators with enhanced properties:
| Company |
Candidate |
Mechanism |
Status |
Notes |
| VARX |
VARX-002 |
Brain-penetrant iron chelator |
Discovery |
Enhanced BBB penetration |
| Various |
CLO (clioquinol) |
Metal-protein attenuation |
Preclinical |
Combined chelator and antioxidant |
| Various |
SBT-272 |
Mitochondrial-targeted iron chelator |
Preclinical |
Targets mitochondrial iron overload |
¶ Research Consortia and Academic Programs
- University of Lille (France): Prof. David Devos, Dr. Caroline Moreau — FAIRPARK clinical program
- European Parkinson's Study Group: Clinical trial network for iron chelation approaches
- Various: Basic research on GPX4 biology, ACSL4 vulnerability, and ferroptosis in dopaminergic neurons
| Company |
Drug |
Mechanism |
Indication |
Stage |
| Apopharma |
Deferiprone |
Iron chelation |
PD |
Phase II completed |
| Novartis |
Deferasirox |
Iron chelation |
PD |
Phase I completed |
| Roche |
Deferoxamine |
Iron chelation |
PD (historical) |
Phase I/II completed |
| Various |
VARX-002 |
Brain-penetrant chelator |
PD |
Discovery |
| Various |
CLO |
Chelator + antioxidant |
PD |
Preclinical |
| Various |
SBT-272 |
Mito-targeted chelator |
PD |
Preclinical |
Deferoxamine (Desferal)
- Established proof that brain iron can be reduced
- Requires subcutaneous or intravenous administration
- Limited BBB penetration
Deferiprone (Ferriprox)
- First oral chelator to show efficacy in PD
- Demonstrated disease-modifying potential in FAIRPARK-II
- Requires weekly CBC monitoring for neutropenia
Deferasirox (Exjade/Jadenu)
- Once-daily oral dosing
- Improved tolerability profile
- Early-phase PD trials completed
- Enhanced BBB Penetration: New chelators with improved brain delivery
- Mitochondrial Targeting: Chelators that specifically target mitochondrial iron overload
- Combined Mechanisms: Chelation + antioxidant activity (e.g., clioquinol)
- Patient Selection: MRI-based R2* or QSM for patient enrichment
Key biomarkers being developed to enrich patient populations:
- MRI biomarkers: R2* or quantitative susceptibility mapping (QSM) to measure brain iron
- Serum markers: Ferritin, transferrin, hepcidin
- CSF markers: Iron, oxidative stress markers
- BBB Penetration: Many chelators do not adequately cross the blood-brain barrier
- Safety Monitoring: Some chelators require regular blood count monitoring
- Timing of Intervention: Iron accumulation occurs early; late intervention may be less effective
- Combination Approaches: Likely needs combination with other neuroprotective strategies